| Q64898943 | A novel RFLP-ARMS TaqMan PCR-based method for detecting the BRAF V600E mutation in melanoma. |
| Q51553861 | A novel high-resolution chipCE assay for rapid detection of EGFR gene mutations and amplifications in lung cancer therapy by a combination of fragment analysis, denaturing CE and MLPA. |
| Q34132010 | Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. |
| Q33756779 | COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma |
| Q35127938 | Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. |
| Q36997408 | Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy |
| Q44193651 | Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. |
| Q39477372 | Competitive amplification of differentially melting amplicons (CADMA) enables sensitive and direct detection of all mutation types by high-resolution melting analysis. |
| Q92256962 | Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC) |
| Q39172118 | Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie |
| Q37916396 | Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review |
| Q37000019 | Diagnostic RAS mutation analysis by polymerase chain reaction (PCR). |
| Q34622391 | Differences in K-ras and mitochondrial DNA mutations and microsatellite instability between colorectal cancers of Vietnamese and Japanese patients. |
| Q39416581 | Differences in the frequencies of K-ras c12-13 genotypes by gender and pathologic phenotypes in colorectal tumors measured using the allele discrimination method |
| Q54380376 | Does a cost-effective approach for the determination of KRAS mutations maximize the patient's benefit in a clinical setting? |
| Q35885555 | Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications |
| Q39654749 | Increased sensitivity of KRAS mutation detection by high-resolution melting analysis of COLD-PCR products |
| Q38932624 | KRAS and BRAF genotyping of synchronous colorectal carcinomas |
| Q34142761 | KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment |
| Q37709506 | KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma |
| Q34748747 | KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer |
| Q28070038 | Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective |
| Q35150642 | Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer |
| Q35541778 | Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience |
| Q47164988 | Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications. |
| Q36289392 | Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective. |
| Q64916419 | Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens. |
| Q33768220 | The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. |
| Q54389429 | Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. |